OVERHIT
2026-08-18 14:15:10
Predicted 2.5% → Actual 16.2%
Argenx announced that Vyvgart achieved its endpoints in a major clinical trial for autoimmune myositis.
If the target price reaches $935.88, take profits, and if it falls to $826.45, cut losses. These two prices are the benchmark values calculated by REPORTING, and no separate technical rationale is provided.
The news is positive, and with the closing price of 992.99 on 2026-08-18 approaching the recent high of 1009.74, we believe there is remaining upward momentum. The RSI is low at 39.1, indicating potential for further increases, prompting us to consider buying.
RSI(14) 39.1 – Approaching oversold levels, moving averages are misaligned – trend is unclear, trading volume is 0.96 times the 20-day average – below average, recent 7-day volatility -1.9% – slight downward trend.
The actual return significantly exceeded the forecasted return of 2.5%, coming in at 16.2%. The decision to buy based on positive news and a low RSI was correct, and although the target price and stop-loss were set lower than the actual movement, the overall upward trend was captured. However, the target price setting was conservative, and there was room to consider a higher target.
In the next trading session, we will continuously utilize positive news and a low RSI as buy signals, while setting the target price at a higher level compared to the current price, and maintaining positions until trading volume recovers to above average. Additionally, considering that the SEC general disclosure does not significantly change the risk, we will maintain the existing strategy while monitoring the decreasing trend of theme news to reflect changes in market interest.
In the past, there was an increase of +8.6% on July 22, 2026, and an increase of +3.3% on July 1, 2026. Additionally, on August 18, 2026, the same ticker (ARGX) recorded a return of 16.2% related to Vyvgart news that included the same keyword 'Vyvgart'. This shows a similarity due to the matching keyword and positive clinical results. However, the success cases of other tickers (VEEE, LRCX) do not have direct similarities and are mentioned for reference only.